CD13 and CD33 myeloid/cross lineage antigens can be expressed and a subset of B-ALL may be Philadelphia chromosome-positive (Ph+), but the myeloid-specific CD117 should not be present and is used to differentiate between ALL and acute myeloid leukemias (AMLs) (Chiaretti et al., 2014; Gupta et al., 2021). This evidence concerns the gene CD33 and acute lymphoblastic leukemia.